Gooderham, Melinda J.
Girolomoni, Giampiero
Moore, Julian O.
Silverberg, Jonathan I.
Bissonnette, Robert
Forman, Seth
Peeva, Elena
Biswas, Pinaki
Valdez, Hernan
Chan, Gary
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
https://doi.org/10.1007/s40262-021-01104-z
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
https://doi.org/10.1007/s13555-022-00764-4
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Funding for this research was provided by:
Pfizer
Article History
Received: 14 April 2022
Accepted: 21 June 2022
First Online: 7 August 2022